RT @Ronaldo_CFF: 6/ Check out this table/fig for the most common anti-inflammatory drugs, some bDMARDs side effects, and bDMARDs most commo…
RT @Ronaldo_CFF: 5/ ARDs are ASCVD risk enhancers ARDs therapy goal: ↑ disease activity as a consequence ↑ CVD risk DMARDs are the corner…
12/ TNFi and IL-6i: ↑ in total cholesterol and LDL ⬇️systemic inflammation Net effect seems to favor ⬇️MACE However, further clinical data w/ longer f/u is needed to settle down this matter https://t.co/8ctq3MbRnp @stergios87
7/ Observational data from different ARD (including vasculitis, lupus, scleroderma) suggests improvement of CVD surrogate variables (CRP, myocardial inflammation by CMR) with bDMARDs bDMARDs⬇️inflammation Ref# 122-134, 141-142 https://t.co/8ctq3MbRnp @
6/ Check out this table/fig for the most common anti-inflammatory drugs, some bDMARDs side effects, and bDMARDs most common pathways bDMARDs w/ particular CVD interest pathway: IL-1 and IL-6 inhibition https://t.co/BtfCnuV7iT https://t.co/8ctq3MbRnp htt
5/ ARDs are ASCVD risk enhancers ARDs therapy goal: ↑ disease activity as a consequence ↑ CVD risk DMARDs are the cornerstone of ARDs, although bDMARDs are not the first line treatment for most ARDs, they have revolutionized ARD management https://t.co/